285 results on '"Fleischhacker, W.W."'
Search Results
2. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST)
3. Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study
4. Adverse Effects of Atypical Antipsychotics
5. Premorbid social functioning and depressive symptoms predict internalized stigma in stable schizophrenia
6. The impact of hemoglobin levels on fatigue and quality of life in cancer patients
7. Quality of life measurement in oncology—a matter of the assessment instrument?
8. Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia
9. Differential effects of antipsychotic drugs on insight in first episode schizophrenia
10. P.3.d.079 Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study
11. P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial
12. EPA-0790 – All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials
13. P.3.d.033 - Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia
14. Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia
15. P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole
16. P.3.f.012 Association between bilirubin and schizophrenia: a longitudinal study
17. P.3.d.049 Expected and effective plasma concentrations of antipsychotic drugs and attitude toward treatment
18. P.1.g.075 Gender differences in routes of drug administration in involuntarily admitted patients – changes from 1997 to 2007
19. P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole
20. P.3.d.048 Expected and effective plasma concentrations of antipsychotics and changes in psychopathology
21. Encouraging a new generation of researchers in a time of limited resources
22. 2277 – A placebo-controlled study of efficacy and safety of aripiprazole once-monthly for long-term maintenance treatment in schizophrenia
23. 2281 – Psychosocial and overall effectiveness of aripiprazole once-monthly vs. placebo once-monthly for maintenance treatment in schizophrenia
24. 2967 – Long-acting injectable antipsychotics in the treatment of schizophrenia
25. P.3.c.053 Relating reported extrapyramidal adverse events to movement disorder rating scales in ziprasidone randomised clinical trials
26. Editorial des Präsidenten
27. Veränderungen psychopharmakologischer Behandlungsstrategien bei Schizophrenie
28. Lessons from schizophrenia study: Eufest
29. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study
30. Large pragmatic long term clinical trials in schizophrenia
31. Toward the reintegration of psychiatry and medicine in patients with mental illness
32. Why it is sometimes difficult to generalize results from RCT's to everyday clinical practice
33. S.14.05 Metabolic side effects of antipsychotics
34. Brain activation pattern during a verbal fluency test in healthy male and female volunteers: a functional magnetic resonance imaging study
35. P.2.061 Long-acting risperidone injection improves and maintains quality of life in patients with schizophrenia
36. Sex differences in brain activation pattern during a visuospatial cognitive task: a functional magnetic resonance imaging study in healthy volunteers
37. Alterations of glucose metabolism during treatment with clozapine versus amisulpride
38. The neural correlates of episodic encoding and recognition of words in unmedicated patients with acute episode of schizophrenia: A functional MRI study
39. Osteoporosis in patients suffering from schizophrenia
40. The first-episode of schizophrenia: a challenge for treatment
41. Executive functions in schizophrenia
42. Long-term safety of long-acting risperidone microspheres
43. Safety, tolerability and compliance in the use of antipsychotics
44. Osteoporosis in young patients with schizophrenia
45. Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment
46. Differential regulation of chromogranin peptides by PCP
47. Alcohol and benzodiazepines — Risk factors in accidents
48. Are schizophrenia and antipsychotic treatment risk factors for osteoporosis?
49. Need for and problems with placebo-controlled studies
50. S32.03 New antipsychotics: The issue of side-effects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.